An open-label, safety, pharmacokinetic and pharmacodynamic study of multiple doses of GW572016 [lapatinib] to examine the inhibition of EGFR/ERB2 phosphorylation in cancer patients with solid tumour

Trial Profile

An open-label, safety, pharmacokinetic and pharmacodynamic study of multiple doses of GW572016 [lapatinib] to examine the inhibition of EGFR/ERB2 phosphorylation in cancer patients with solid tumour

Not stated
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2007

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 28 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top